v3.26.1
Note 12 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Research and development expense $ 13,390 $ 13,054
General and administrative expense 6,909 4,912
Other income 1,982 1,333
Net loss (18,317) (16,633)
Personnel [Member]    
Research and development expense 4,592 3,199
General and administrative expense 4,914 3,301
General [Member]    
Research and development expense 1,336 1,213
General and administrative expense 1,995 1,611
Tovecimig [Member]    
Research and development expense 4,976 6,677
CTX-471 [Member]    
Research and development expense 858 699
CTX-8371 [Member]    
Research and development expense 783 529
CTX-10726 [Member]    
Research and development expense $ 845 $ 737